Evidence map›Paper›PMID 42743071›Full record

SynthesisEuropean journal of clinical investigation2026

Prevalence of Cancer Across Cardiovascular and Cardiometabolic Conditions: A Systematic Review and Meta-Analysis.

Akhmetzhan Galimzhanov, Elif Beytekin, Leh Chuan Lim, Abdul Basit Ali Zai, Gemina Doolub, Mustafa Aljarshawi, Balamrit Singh Sokhal, Andrija Matetic, Rodrigo Bagur, Louise Y Sun and 5 more

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in European journal of clinical investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Akhmetzhan GalimzhanovDepartment of Internal Medicine No 1, Astana Medical University, Astana, Kazakhstan.ORCID https://orcid.org/0000-0002-1605-9512
Elif BeytekinKeele Cardiovascular Research Group, Keele University, Keele, UK.
Leh Chuan LimKeele Cardiovascular Research Group, Keele University, Keele, UK.ORCID https://orcid.org/0000-0001-5825-7325
Abdul Basit Ali ZaiKeele Cardiovascular Research Group, Keele University, Keele, UK.
Gemina DoolubKeele Cardiovascular Research Group, Keele University, Keele, UK.ORCID https://orcid.org/0000-0002-3089-2690
Mustafa AljarshawiKeele Cardiovascular Research Group, Keele University, Keele, UK.ORCID https://orcid.org/0000-0002-4600-2701
Balamrit Singh SokhalKeele Cardiovascular Research Group, Keele University, Keele, UK.ORCID https://orcid.org/0000-0002-2315-0744
Andrija MateticKeele Cardiovascular Research Group, Keele University, Keele, UK.ORCID https://orcid.org/0000-0001-9272-6906
Rodrigo BagurDepartment of Cardiology, London Health Sciences Centre, Western University, London, Ontario, Canada.ORCID https://orcid.org/0000-0003-1888-9429
Louise Y SunDivision of Cardiothoracic Anesthesiology, Stanford University School of Medicine, Stanford, California, USA.ORCID https://orcid.org/0000-0003-3381-3115
Cheng Han NgDivision of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore, Singapore.ORCID https://orcid.org/0000-0002-8297-1569
Miguel Nobre MenezesStructural and Coronary Heart Disease Unit, Cardio-Oncology Unit CHULN Hospital de Santa Maria, Cardiovascular Center of the University of Lisbon, Lisbon, Portugal.ORCID https://orcid.org/0000-0001-8363-0363
Sarah ZamanWestmead Applied Research Centre, University of Sydney, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0001-6289-583X
Bonnie KyThalheimer Center for Cardio-Oncology, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0000-0002-6628-9981
Mamas A MamasKeele Cardiovascular Research Group, Keele University, Keele, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo the best of our knowledge, no previous systematic review has comprehensively quantified cancer prevalence across the broad spectrum of cardiovascular and cardiometabolic conditions included in the present study. We aimed to estimate pooled prevalence of active cancer (primary outcome) and other cancer categories among patients with coronary artery disease (CAD), heart failure (HF), atrial fibrillation (AF), hypertension, Type 2 diabetes mellitus (DM), stroke, peripheral artery disease (PAD), and valvular heart disease (VHD).

methodsPubMed, Web of Science, and Scopus were searched from 2010 to July 2024. Secondary outcomes included prevalence of any, previous, haematological, solid, and metastatic cancer. Prevalence estimates were calculated using one-step generalized linear mixed models.

resultsA total of 676 studies comprising approximately 180 million participants were included. The primary analysis of active cancer included 59 studies (4,759,695 patients). Active cancer prevalence ranged from 4.22% (95% confidence interval [CI] 2.18-5.32) in Type 2 DM to 5.55% (95% CI 3.97-7.01) in AF. The prevalence of any cancer, a secondary outcome with more heterogeneous ascertainment, ranged from 7.04% (95% CI 6.05-8.03) in CAD to 14.10% (95% CI 12.20-15.99) in AF.

conclusionCancer represents a substantial comorbidity across cardiovascular and cardiometabolic conditions. Although cancer ascertainment methods varied across studies, particularly for any cancer, the findings provide contemporary estimates of cancer burden that may inform future cardio-oncology research, healthcare planning, risk stratification, and the design of cardiovascular and cardiometabolic clinical trials.

trial registrationPROSPERO CRD42023494764.

Indexed as

Cardiovascular DiseasesNeoplasmsAtrial FibrillationCoronary Artery DiseaseDiabetes Mellitus, Type 2Heart FailureHeart Valve DiseasesHumansHypertensionPeripheral Arterial DiseasePrevalenceStrokeatrial fibrillationcancer statisticscardio‐oncologycardiovascular diseaseheart failureprevalence

Identifiers

PMID42743071
PMCPMC13577239

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.